Does Adam Stavisky pay a price per share for these Omada Health RSUs?

The Form 4 shows a transaction price per share of 0.0000 for the 10,882 RSUs. This indicates the RSUs were granted without a cash purchase price, with shares delivered upon vesting under the stated schedule and service conditions.

Omada Health (OMDA) director awarded 10,882 RSUs vesting by 2027

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Stavisky Adam reported acquisition or exercise transactions in this Form 4 filing.

Omada Health, Inc. director Adam Stavisky reported receiving a grant of 10,882 restricted stock units (RSUs), each convertible into one share of Common Stock at no cost when vested.

All RSUs vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting, subject to continued service, bringing his direct holdings to 20,618 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stavisky Adam

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,882	$0.00	--

Holdings After Transaction: Common Stock — 20,618 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 10,882 RSUs Transaction price per share: $0.0000 per share Shares held after grant: 20,618 shares +1 more

4 metrics

RSUs granted 10,882 RSUs Grant of restricted stock units to director on 2026-06-16

Transaction price per share $0.0000 per share RSU grant with no cash purchase price

Shares held after grant 20,618 shares Total direct holdings following reported acquisition

Vesting trigger 100% on earlier of 1-year or 2027 meeting RSUs vest on first anniversary of grant or 2027 Annual Meeting, with service condition

Key Terms

restricted stock units ("RSUs"), vesting, Annual Meeting

3 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vesting financial

"one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs will fully vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting financial

"the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/18/2026 - 04:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stavisky Adam

(Last)

(First)

(Middle)

C/O OMADA HEALTH, INC.

611 GATEWAY BLVD., SUITE 120

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Omada Health, Inc. [ OMDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2026		A		10,882⁽¹⁾	A	$0	20,618	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs will fully vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, subject to continued service through such vesting date.

	/s/ Nathan Salha, as Attorney-in-Fact for Adam Stavisky	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Omada Health (OMDA) director Adam Stavisky report on this Form 4?

Adam Stavisky reported receiving 10,882 restricted stock units (RSUs) of Omada Health Common Stock. These RSUs entitle him to one share per unit upon vesting, increasing his direct holdings to 20,618 shares after the reported grant.

How many Omada Health RSUs were granted to Adam Stavisky?

Adam Stavisky was granted 10,882 restricted stock units (RSUs) of Omada Health Common Stock. Each RSU converts into one share upon vesting, with no purchase price per share disclosed in the transaction details of this Form 4 filing.

What is the vesting schedule for Adam Stavisky’s Omada Health RSUs?

All 10,882 RSUs will vest 100% on the earlier of the first anniversary of the grant date or the date of Omada Health’s 2027 Annual Meeting of stockholders, provided Adam Stavisky remains in service through that vesting date.

How many Omada Health shares does Adam Stavisky hold after this RSU grant?

Following the RSU grant, Adam Stavisky’s total reported direct holdings are 20,618 shares of Omada Health Common Stock. This figure reflects his position after the acquisition reported in this Form 4, according to the filing’s transaction table.

Are there any derivative securities reported for Adam Stavisky in this Omada Health Form 4?

The Form 4 derivative summary is empty, indicating no additional derivative securities, such as options or warrants, are reported in this specific filing for Adam Stavisky beyond the 10,882 RSUs described in the non-derivative transaction table.